




Pharmaceutical Dosage Forms and Drug Delivery

Third Edition



Ram I. Mahato and Ajit S. Narang

 CRC Press
Taylor & Francis Group

 CPD
CERTIFIED
The CPD Certification
Service

Pharmaceutical Dosage Forms and Drug Delivery



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Pharmaceutical Dosage Forms and Drug Delivery

Third Edition: Revised and Expanded

by

Ram I. Mahato, PhD

Department of Pharmaceutical Sciences,
University of Nebraska Medical Center
Omaha, NE

Ajit S. Narang, PhD

Small Molecule Pharmaceutical Sciences, Genentech, Inc.
One DNA Drive, South San Francisco, CA



CRC Press

Taylor & Francis Group
Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2018 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper

International Standard Book Number-13: 978-1-4822-5362-7 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Names: Mahato, Ram I., author. | Narang, Ajit S., author.
Title: Pharmaceutical dosage forms and drug delivery : third edition, revised and expanded / Ram I. Mahato and Ajit S. Narang.
Description: Third edition. | Boca Raton : CRC Press, [2017] | Includes bibliographical references and index.
Identifiers: LCCN 2017017702 | ISBN 9781482253627 (hardback : alk. paper) | ISBN 9781315156941 (ebook)
Subjects: LCSH: Drugs--Dosage forms. | Drug delivery systems.
Classification: LCC RS200 .M34 2017 | DDC 615.1/9--dc23
LC record available at <https://lcn.loc.gov/2017017702>

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

I dedicate this book to my wife Subhashini, my children Kalika and Vivek for their love and support; my late mother Sarswati for believing in me; and to my students and mentors who have always helped me in my quest for learning and in achieving higher goals.

Ram I. Mahato

To Tirath Singh and Gurdip Kaur, my parents, who taught me simplicity, sincerity, and hard work.

Ajit S. Narang



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Contents

<i>Foreword</i>	xxxix
<i>Preface</i>	xxxiii
<i>Acknowledgments</i>	xxxv
<i>About the authors</i>	xxxvii
PART I	
Introductory chapters	I
1 Drug discovery	3
1.1 <i>Introduction</i>	3
1.1.1 <i>Elements of drug discovery</i>	4
1.1.2 <i>Sources of drugs</i>	6
1.1.2.1 <i>Plant sources</i>	6
1.1.2.2 <i>Organic synthesis</i>	7
1.1.2.3 <i>Use of animals</i>	7
1.1.2.4 <i>Genetic engineering</i>	7
1.1.2.5 <i>Gene therapy</i>	8
1.2 <i>Collaborating disciplines</i>	8
1.2.1 <i>Biology</i>	9
1.2.2 <i>Chemistry</i>	10
1.2.3 <i>Pharmaceutics</i>	11
1.2.4 <i>Animal toxicology</i>	11
1.2.5 <i>Clinical pharmacology</i>	12
1.2.6 <i>Analytical and bioanalytical sciences</i>	12
1.2.7 <i>Regulatory sciences</i>	13
1.3 <i>Small- versus large-molecule paradigms</i>	14
1.3.1 <i>Preclinical discovery and toxicology assessment</i>	17
1.3.2 <i>Pharmaceutical development</i>	18
1.3.3 <i>Clinical development</i>	18

1.4 *Contemporary drug discovery case studies* 18

1.4.1 *Statins* 18

1.4.2 *Immuno-oncology* 19

1.5 *Summary and outlook to the future* 21

Review questions 21

References 22

Further reading 23

2 Drug development 25

2.1 *Introduction* 25

2.2 *Stage-gate process of new drug discovery and development* 29

2.2.1 *Preclinical development* 30

2.2.1.1 *Physicochemical characterization* 30

2.2.1.2 *Efficacy studies* 30

2.2.1.3 *Toxicology studies* 31

2.2.2 *Clinical development* 31

2.2.2.1 *Phase I clinical trials* 33

2.2.2.2 *Phase II clinical trials* 33

2.2.2.3 *Phase III clinical trials* 34

2.2.2.4 *Evolving clinical development paradigms* 34

2.3 *Pharmaceutical development* 35

2.3.1 *Preformulation and formulation studies* 36

2.3.2 *Stage-appropriate drug product design* 36

2.3.3 *Stability* 36

2.3.4 *Bioavailability* 37

2.3.5 *Manufacturability* 38

2.4 *Regulatory approval* 38

2.4.1 *Investigational new drug application* 39

2.4.2 *New drug application* 40

2.4.2.1 *Basis of approval* 40

2.4.2.2 *Role of advisory committees* 40

2.4.3 *Biologics license application* 41

2.4.4 *Abbreviated new drug application* 41

2.4.5 *Biosimilars* 42

2.4.6 *Approval and postmarketing surveillance* 42

2.4.7 *Accelerated development/review* 42

2.5 *Postcommercialization activities* 43

2.5.1 *Manufacturing support* 43

2.5.2 *Intellectual property* 43

2.5.3 *Life cycle management* 44

Review questions 45

Further reading 47

3 Pharmaceutical considerations 49

3.1 *Introduction* 49

3.2 *Advantages of pharmaceutical dosage forms* 50

3.3 *Influential factors in dosage form design* 51

3.3.1 *Molecular size and volume* 51

3.3.2 *Drug solubility and pH* 53

3.3.3 *Lipophilicity and partition coefficient* 55

3.3.4 *Polymorphism* 58

3.3.5 *Stability* 59

3.3.6 *pK_a/Dissociation constants* 60

3.3.7 *Degree of ionization and pH-partition theory* 63

3.3.7.1 *Limitations of pH-partition theory* 64

Review questions 65

Further reading 66

4 Biopharmaceutical considerations 69

4.1 *Introduction* 69

4.2 *Diffusion* 70

4.2.1 *Drug transport across a polymeric barrier* 70

4.2.1.1 *Molecular diffusion* 70

4.2.1.2 *Pore diffusion* 71

4.2.1.3 *Matrix erosion* 71

4.2.2 *Principles of diffusion* 72

4.2.2.1 *Fick's first law* 72

4.2.2.2 *Fick's second law* 73

4.2.3 *Diffusion rate* 73

4.2.3.1 *Diffusion cell* 74

4.2.3.2 *Spherical membrane-controlled drug delivery system* 75

4.2.3.3 *Pore diffusion* 76

4.2.3.4 *Determining permeability coefficient* 76

4.2.3.5 *Lag time in non-steady state diffusion* 77

4.2.3.6 *Matrix (monolithic)-type non-degradable system* 77

4.2.3.7 *Calculation examples* 78

- 4.3 *Dissolution* 79
 - 4.3.1 *Noyes–Whitney equation* 79
 - 4.3.2 *Calculation example* 80
 - 4.3.3 *Factors influencing dissolution rate* 81
- 4.4 *Absorption* 83
 - 4.4.1 *Passive transport* 85
 - 4.4.1.1 *Simple diffusion* 85
 - 4.4.1.2 *Carrier-mediated transport* 85
 - 4.4.1.3 *Channel-mediated transport* 86
 - 4.4.1.4 *Fick’s laws of diffusion in drug absorption* 86
 - 4.4.2 *Active transport* 87
- Review questions* 87
- Further reading* 89

5 Pharmacy math and statistics

91

- 5.1 *Introduction* 91
- 5.2 *Systems of measure* 92
 - 5.2.1 *Volume and weight interconversions* 93
 - 5.2.2 *Temperature interconversions* 93
 - 5.2.3 *Accuracy, precision, and significant figures* 94
- 5.3 *Ratio and proportion* 94
- 5.4 *Concentration calculations* 95
 - 5.4.1 *Percentage solutions* 95
 - 5.4.2 *Concentrations based on moles and equivalents* 96
 - 5.4.3 *Parts per unit concentrations* 97
 - 5.4.4 *Dilution of stock solutions* 98
 - 5.4.5 *Mixing solutions of different concentrations* 99
 - 5.4.5.1 *Alligation medial* 99
 - 5.4.5.2 *Alligation alternate* 100
 - 5.4.6 *Tonicity, osmolarity, and preparation of isotonic solutions* 102
- 5.5 *Clinical dose calculations* 106
 - 5.5.1 *Dosage adjustment based on body weight or surface area* 106
 - 5.5.2 *Calculation of children’s dose* 107
 - 5.5.3 *Dose adjustment for toxic compounds* 110
 - 5.5.4 *Dose adjustment based on creatinine clearance* 111

- 5.6 *Statistical measures* 112
 - 5.6.1 *Measures of central tendency* 113
 - 5.6.2 *Measures of dispersion* 114
 - 5.6.3 *Sample probability distributions* 115
 - 5.6.3.1 *Normal distribution* 116
 - 5.6.3.2 *Log-normal distribution* 116
 - 5.6.3.3 *Binomial distribution* 116
 - 5.6.3.4 *Poisson distribution* 116
 - 5.6.3.5 *Student's t-distribution* 116
 - 5.6.3.6 *Chi-square distribution* 118
 - 5.7 *Tests of statistical significance* 119
 - 5.7.1 *Parametric and nonparametric tests* 120
 - 5.7.2 *Null and alternate hypothesis* 120
 - 5.7.3 *Steps of hypothesis testing* 121
 - 5.7.4 *One-tailed and two-tailed hypothesis tests* 121
 - 5.7.5 *Regions of acceptance and rejection* 122
 - 5.7.6 *Probability value and power of a test* 123
 - 5.7.7 *Types of error* 124
 - 5.7.8 *Questions addressed by tests of significance* 124
 - 5.7.9 *Analysis of variance* 128
 - 5.7.9.1 *One-way ANOVA* 128
 - 5.7.9.2 *Two-way ANOVA: Design of experiments* 135
- Review questions* 140
- References* 143

PART II

Physicochemical principles

145

6 Complexation and protein binding

147

- 6.1 *Introduction* 147
- 6.2 *Types of complexes* 150
 - 6.2.1 *Coordination complexes* 151
 - 6.2.2 *Molecular complexes* 152
 - 6.2.2.1 *Small molecule–small molecule complexes* 152
 - 6.2.2.2 *Small molecule–large molecule complexes* 153
 - 6.2.2.3 *Large molecule–large molecule complexes* 155

- 6.3 *Protein binding* 156
 - 6.3.1 *Kinetics of ligand–protein binding* 156
 - 6.3.1.1 *Parameters of interest* 157
 - 6.3.1.2 *Experimental setup* 157
 - 6.3.1.3 *Determining k_a and y_{max}* 157
 - 6.3.2 *Thermodynamics of ligand–protein binding* 160
 - 6.3.3 *Factors influencing protein binding* 162
 - 6.3.3.1 *Physicochemical characteristics and concentration of the drug* 162
 - 6.3.3.2 *Physicochemical characteristics and concentration of the protein* 163
 - 6.3.3.3 *Physicochemical characteristics of the medium* 163
 - 6.3.4 *Plasma protein binding* 163
 - 6.3.4.1 *Plasma proteins involved in binding* 164
 - 6.3.4.2 *Factors affecting plasma–protein binding* 164
 - 6.3.4.3 *Consequences of plasma–protein binding* 164
 - 6.3.5 *Drug receptor binding* 166
 - 6.3.6 *Substrate enzyme binding* 166
- Review questions* 167
- Further reading* 168

7 Chemical kinetics and stability

169

- 7.1 *Introduction* 169
- 7.2 *Reaction rate and order* 170
 - 7.2.1 *Pseudo-nth order reactions* 172
 - 7.2.2 *Determining the order of a reaction* 172
 - 7.2.3 *Zero-order reactions* 173
 - 7.2.3.1 *Rate equation* 173
 - 7.2.3.2 *Half-life* 174
 - 7.2.4 *First-order reactions* 175
 - 7.2.4.1 *Rate equation* 175
 - 7.2.4.2 *Half-life* 177
 - 7.2.5 *Second-order reactions* 177
 - 7.2.5.1 *Rate equation* 178
 - 7.2.5.2 *Half-life* 179

- 7.2.6 *Complex reactions* 180
 - 7.2.6.1 *Reversible reactions* 180
 - 7.2.6.2 *Parallel reactions* 180
 - 7.2.6.3 *Consecutive reactions* 181
- 7.3 *Factors affecting reaction kinetics* 182
 - 7.3.1 *Temperature* 182
 - 7.3.1.1 *Arrhenius equation* 182
 - 7.3.1.2 *Shelf life* 183
 - 7.3.1.3 *Thermodynamics of reactions* 184
 - 7.3.2 *Humidity* 185
 - 7.3.2.1 *Water as a reactant* 185
 - 7.3.2.2 *Water as a plasticizer* 185
 - 7.3.2.3 *Water as a solvent* 186
 - 7.3.2.4 *Determination and modeling the effect of water/humidity* 186
 - 7.3.3 *pH* 187
 - 7.3.3.1 *Disproportionation effect* 187
 - 7.3.3.2 *Acid–base catalysis* 187
 - 7.3.3.3 *pH–rate profile* 188
 - 7.3.4 *Cosolvent and additives* 189
 - 7.3.4.1 *Drug–excipient interactions* 189
 - 7.3.4.2 *Catalysis* 190
- 7.4 *Drug degradation pathways* 191
 - 7.4.1 *Hydrolysis* 191
 - 7.4.1.1 *Ester hydrolysis* 192
 - 7.4.1.2 *Amide hydrolysis* 193
 - 7.4.1.3 *Control of drug hydrolysis* 194
 - 7.4.2 *Oxidation* 194
 - 7.4.2.1 *Control of drug oxidation* 196
 - 7.4.3 *Photolysis* 197
 - 7.4.3.1 *Control of photodegradation of drugs* 198
- 7.5 *Stabilization strategies* 199
- Review questions* 199
- Further reading* 201

8 Interfacial phenomena

203

- 8.1 *Introduction* 203
- 8.2 *Liquid–liquid and liquid–gas interfaces* 204
 - 8.2.1 *Surface tension* 205
 - 8.2.2 *Interfacial tension* 206

- 8.2.3 *Factors affecting surface tension* 206
- 8.2.4 *Surface free energy* 207
- 8.3 *Solid–gas interface* 207
 - 8.3.1 *Adsorption* 207
 - 8.3.2 *Factors affecting adsorption* 208
 - 8.3.3 *Types of adsorption* 208
 - 8.3.3.1 *Physical adsorption* 208
 - 8.3.3.2 *Chemical adsorption (chemisorption)* 209
 - 8.3.4 *Adsorption isotherms* 210
 - 8.3.4.1 *Type of isotherms* 210
 - 8.3.4.2 *Modeling isothermal adsorption* 211
- 8.4 *Solid–Liquid interface* 214
 - 8.4.1 *Modeling solute adsorption* 214
 - 8.4.2 *Factors affecting adsorption from solution* 215
 - 8.4.3 *Wettability and wetting agents* 216
- 8.5 *Biological and pharmaceutical applications* 217
- Review questions* 218
- Reference* 218
- Further reading* 219

9 Colloidal dispersions

221

- 9.1 *Introduction* 221
- 9.2 *Types of colloidal systems* 222
 - 9.2.1 *Lyophilic colloids* 223
 - 9.2.2 *Lyophobic colloids* 223
 - 9.2.3 *Association colloids* 223
- 9.3 *Preparation of colloidal solutions* 224
- 9.4 *Properties of colloidal solutions* 225
 - 9.4.1 *Kinetic properties* 225
 - 9.4.1.1 *Brownian movement* 225
 - 9.4.1.2 *Diffusion* 225
 - 9.4.1.3 *Sedimentation* 227
 - 9.4.2 *Electrical properties* 228
 - 9.4.2.1 *Surface charge* 228
 - 9.4.2.2 *Electrical double layer* 231
 - 9.4.2.3 *Electrophoresis* 233
 - 9.4.3 *Colligative properties* 233
 - 9.4.3.1 *Lowering of vapor pressure* 233
 - 9.4.3.2 *Elevation of boiling point* 234

- 9.4.3.3 Depression of freezing point 234
- 9.4.3.4 Osmotic pressure 235
- 9.4.4 Optical properties 235
- 9.5 Physical stability of colloids 236
 - 9.5.1 Stabilization of hydrophilic colloids 236
 - 9.5.2 Stabilization of hydrophobic colloids 237
- Review questions 237
- Further reading 239

10 Surfactants and micelles 241

- 10.1 Introduction 241
- 10.2 Surfactants 242
 - 10.2.1 Types of surfactants 243
 - 10.2.1.1 Anionic surfactants 244
 - 10.2.1.2 Cationic surfactants 244
 - 10.2.1.3 Nonionic surfactants 245
 - 10.2.1.4 Ampholytic surfactants 246
 - 10.2.2 Hydrophile–lipophile balance system 246
 - 10.2.2.1 Type of emulsion formed 247
 - 10.2.2.2 Required HLB of a lipid 248
 - 10.2.2.3 Required HLB of a formulation 249
 - 10.2.2.4 Assigning a hydrophile–lipophile balance value to a surfactant 249
 - 10.2.2.5 Selection of surfactant combination for a target hydrophile–lipophile balance value 250
- 10.3 Micelles 250
 - 10.3.1 Types of micelles 251
 - 10.3.2 Micelles versus liposomes 251
 - 10.3.3 Colloidal properties of micellar solutions 252
 - 10.3.4 Factors affecting critical micelle concentration and micellar size 254
 - 10.3.5 Krafft point 255
 - 10.3.6 Cloud point 255
 - 10.3.7 Micellar solubilization 256
 - 10.3.7.1 Factors affecting the extent of solubilization 256
 - 10.3.7.2 Pharmaceutical applications 258
 - 10.3.7.3 Thermodynamics/spontaneity 259
- Review questions 260
- Further reading 261

11	Pharmaceutical polymers	263
11.1	<i>Introduction</i>	263
11.2	<i>Definitions and architectures of polymers</i>	264
11.3	<i>Polymer molecular weight and weight distribution</i>	268
11.4	<i>Biodegradability and biocompatibility</i>	269
11.5	<i>Physicochemical properties and solubility</i>	270
11.6	<i>Block copolymers</i>	271
11.7	<i>Intelligent or stimuli-sensitive polymers</i>	272
11.7.1	<i>pH-Responsive polymers</i>	274
11.7.2	<i>Thermosensitive polymers</i>	276
11.7.3	<i>Other stimuli-responsive polymers</i>	276
11.8	<i>Water-soluble polymers</i>	277
11.8.1	<i>Carboxypolymethylene (carbomer, carbopol)</i>	278
11.8.2	<i>Cellulose derivatives</i>	278
11.8.3	<i>Natural gum (acacia)</i>	278
11.8.4	<i>Alginates</i>	278
11.8.5	<i>Dextran</i>	279
11.8.6	<i>Polyvinylpyrrolidone</i>	279
11.8.7	<i>Polyethylene glycol</i>	279
11.9	<i>Bioadhesive/mucoadhesive polymers</i>	279
11.9.1	<i>Advantages of mucoadhesive drug delivery systems</i>	281
11.9.2	<i>Mechanism of mucoadhesion</i>	281
11.9.3	<i>Quantitation of mucoadhesion</i>	281
11.9.4	<i>Sites of application</i>	282
11.9.5	<i>Dosage forms</i>	282
11.9.6	<i>Transdermal patches</i>	283
	<i>Review questions</i>	283
	<i>References</i>	284
	<i>Further reading</i>	284
12	Rheology	287
12.1	<i>Introduction</i>	287
12.2	<i>Newtonian flow</i>	288
12.2.1	<i>Temperature dependence and viscosity of liquids</i>	289
12.3	<i>Non-Newtonian flow</i>	290
12.3.1	<i>Plastic flow</i>	290
12.3.2	<i>Pseudoplastic (shear-thinning) flow</i>	291
12.3.3	<i>Dilatant (shear-thickening) flow</i>	291

12.4	<i>Thixotropy</i>	292	
12.4.1	<i>Hysteresis loop</i>	293	
12.5	<i>Pharmaceutical applications of rheology</i>	295	
	<i>Review questions</i>	296	
	<i>Further reading</i>	297	
13	Radiopharmaceuticals		299
13.1	<i>Introduction</i>	299	
13.1.1	<i>Types of radiation</i>	300	
13.1.2	<i>Units of radioactivity</i>	301	
13.1.3	<i>Radiation safety</i>	302	
13.2	<i>Biomedical applications of radiopharmaceuticals</i>	303	
13.2.1	<i>Radioactive tracers and diagnosis</i>	303	
13.2.2	<i>Radiotherapy</i>	304	
13.3	<i>Radiation detection equipment</i>	305	
13.4	<i>Formulation of radiopharmaceuticals</i>	307	
13.5	<i>Calculations</i>	308	
	<i>Review questions</i>	309	
14	Drug delivery systems		313
14.1	<i>Introduction</i>	313	
14.2	<i>Targeted drug delivery</i>	314	
14.3	<i>Prodrugs</i>	316	
14.4	<i>Soluble macromolecular carriers</i>	317	
14.5	<i>Particulate carrier systems</i>	319	
14.5.1	<i>Liposomes</i>	319	
14.5.1.1	<i>Types of liposomes</i>	320	
14.5.1.2	<i>Fabrication of liposomes</i>	321	
14.5.2	<i>Microparticles and nanoparticles</i>	323	
14.5.2.1	<i>Fabrication of microparticulates</i>	323	
14.5.3	<i>Nanoparticles</i>	328	
14.6	<i>Oral drug delivery</i>	329	
14.7	<i>Alternative routes of delivery</i>	330	
14.7.1	<i>Buccal and sublingual drug delivery</i>	330	
14.7.2	<i>Nasal drug delivery</i>	331	
14.7.3	<i>Pulmonary drug delivery</i>	332	
14.7.4	<i>Ocular drug delivery</i>	332	
14.7.5	<i>Rectal drug delivery</i>	333	
14.7.6	<i>Vaginal drug delivery</i>	333	

Review questions 334

References 335

Further reading 335

15 Organ-specific drug delivery 337

15.1 *Introduction* 337

15.2 *Need for alternate, nonoral routes to the systemic circulation* 338

15.2.1 *Rectal drug delivery* 339

15.2.2 *Vaginal drug delivery* 340

15.2.3 *Transdermal drug delivery* 340

15.2.4 *Buccal and sublingual drug delivery* 341

15.2.5 *Nasal drug delivery* 341

15.2.5.1 *Barriers to transnasal drug delivery* 342

15.2.5.2 *Drug delivery to the brain through the nasal route* 342

15.2.5.3 *Formulation factors affecting transnasal drug delivery* 343

15.3 *Need for organ specific and targeted drug delivery* 343

15.3.1 *Advantages of targeted drug delivery* 344

15.3.2 *Examples of established drug targeting strategies* 344

15.3.2.1 *Pulmonary drug delivery* 345

15.4 *Local drug delivery to the lung* 346

15.5 *Systemic drug delivery through the lung* 346

15.6 *Devices for pulmonary drug delivery* 347

15.6.1 *Ocular drug delivery* 349

15.6.1.1 *Structure of the eye* 349

15.6.1.2 *Routes of drug administration into the eye* 350

15.6.1.3 *Challenges to ocular drug delivery* 351

15.6.1.4 *Physicochemical characteristics of the drug for ocular absorption* 352

15.6.1.5 *Approaches for enhancing drug delivery to the eye* 352

15.6.2 *Brain targeted drug delivery* 354

15.6.2.1 *Blood–brain barrier* 354

15.6.2.2 *Drug delivery strategies to the brain* 355

15.6.3 *Liver-targeted drug delivery* 356

15.6.3.1 *Cellular components of the liver* 356

15.6.3.2 *Common diseases of the liver* 357

15.6.3.3	Natural mechanisms of hepatic drug uptake	358
15.6.3.4	Cellular targets for disease therapy	359
15.6.4	Colon-targeted drug delivery	360
15.6.4.1	Utilization of the unique colonic microflora	361
15.6.4.2	pH-dependent dosage forms	363
15.6.4.3	Time-dependent drug release	364
15.6.4.4	Osmotically controlled drug delivery systems	365
15.7	Combination and other strategies for colon targeting	367
15.7.1	Kidney-targeted drug delivery	369
15.7.1.1	Cellular drug targets	369
15.7.1.2	Particulate systems	370
15.7.1.3	The prodrug approach	372
15.7.1.4	Bioconjugation approaches	373
	Review questions	376
	References	378

PART III

Dosage forms 385

16 Suspensions 387

16.1	Introduction	387
16.2	Types of suspensions	388
16.3	Powder for suspension	389
16.4	Quality attributes	390
16.5	Formulation considerations	393
16.5.1	Flocculation	396
16.5.2	Quantitating the degree of flocculation	400
16.5.3	Physics of particle sedimentation: Stokes' law	401
16.6	Manufacturing process	402
	Review questions	403
	Further reading	404

17 Emulsions 407

17.1	Introduction	407
17.2	Types of emulsions	408
17.2.1	Oil-in-water emulsion	408
17.2.2	Water-in-oil emulsion	409

- 17.2.3 *Multiple emulsions* 409
- 17.2.4 *Microemulsions* 410
 - 17.2.4.1 *Self-emulsifying drug delivery systems and self-microemulsifying drug delivery systems* 410
- 17.3 *Quality attributes* 411
- 17.4 *Formulation considerations* 413
 - 17.4.1 *Minimization of interfacial free energy* 413
 - 17.4.2 *Optimum-phase ratio* 414
 - 17.4.3 *Size, viscosity, and density: Stoke's law* 414
 - 17.4.4 *Zeta potential* 415
- 17.5 *Emulsification* 416
 - 17.5.1 *Mechanisms of emulsification* 416
 - 17.5.2 *Surfactants* 416
 - 17.5.2.1 *Ionic and nonionic surfactants* 417
 - 17.5.2.2 *Hydrophile-lipophile balance value* 417
 - 17.5.3 *Hydrophilic colloids* 418
 - 17.5.4 *Finely divided solid particles* 418
- 17.6 *Manufacturing process* 418
- 17.7 *Stability* 419
 - 17.7.1 *Physical instability* 419
 - 17.7.1.1 *Creaming and sedimentation* 420
 - 17.7.1.2 *Aggregation, coalescence, creaming, and breaking* 420
 - 17.7.1.3 *Phase inversion* 421
 - 17.7.2 *Chemical instability* 421
 - 17.7.3 *Microbial growth* 421
- Review questions* 421
- Further reading* 423

18 Pharmaceutical solutions

425

- 18.1 *Introduction* 425
- 18.2 *Types of solutions* 426
 - 18.2.1 *Syrup* 426
 - 18.2.2 *Elixir* 427
 - 18.2.3 *Tincture* 427
 - 18.2.4 *Oil-based solutions* 428
 - 18.2.5 *Miscellaneous solutions* 428
 - 18.2.6 *Dry or lyophilized mixtures for solution* 428
- 18.3 *Quality attributes* 428
- 18.4 *Formulation components and manufacturing process* 429

- 18.5 *Solubility* 430
 - 18.5.1 *pH and buffer capacity* 430
 - 18.5.1.1 *pH and buffering capacity* 431
 - 18.5.2 *Surfactants and cosolvents* 433
- 18.6 *Stability* 433
 - 18.6.1 *Physical stability* 433
 - 18.6.2 *Chemical stability* 434
 - 18.6.3 *Microbial stability* 435
- Review questions* 435
- Further reading* 436

19 Powders and granules 437

- 19.1 *Introduction* 437
- 19.2 *Production of powders and granules* 438
 - 19.2.1 *Origin of powdered excipients* 438
 - 19.2.2 *Origin of powdered active pharmaceutical ingredients* 440
 - 19.2.3 *Amorphous and crystalline powders* 440
 - 19.2.4 *Production of crystalline powders* 440
 - 19.2.4.1 *Crystallization versus dissolution* 441
 - 19.2.4.2 *Polymorphism* 441
 - 19.2.5 *Production of amorphous powders* 443
- 19.3 *Analyses of powders* 443
 - 19.3.1 *Particle shape and size* 444
 - 19.3.1.1 *Defining particle shape and size* 444
 - 19.3.1.2 *Defining particle size distribution* 445
 - 19.3.1.3 *Desired particle shape and size* 448
 - 19.3.1.4 *Factors determining particle shape* 448
 - 19.3.1.5 *Techniques for quantifying particle shape and size* 449
 - 19.3.1.6 *Changing particle shape and size* 450
 - 19.3.2 *Surface area* 453
 - 19.3.2.1 *Significance of surface area* 453
 - 19.3.2.2 *Defining surface area* 453
 - 19.3.2.3 *Quantitation of surface area by gas adsorption* 454
 - 19.3.2.4 *Altering powder surface area* 455
 - 19.3.3 *Density and porosity* 456
 - 19.3.3.1 *Significance of density determination* 456
 - 19.3.3.2 *Defining powder density* 456

- 19.3.3.3 *Methods for quantifying powder density and porosity* 457
- 19.3.3.4 *Changing powder density and porosity* 459
- 19.3.4 *Flow* 459
 - 19.3.4.1 *Importance of flowability of powders* 459
 - 19.3.4.2 *Factors influencing flow of powders* 460
 - 19.3.4.3 *Quantitation of powder flow* 460
 - 19.3.4.4 *Manipulation of flow properties of powders* 461
- 19.3.5 *Compactibility* 461
 - 19.3.5.1 *Compressibility, compactibility, and tabletability* 461
 - 19.3.5.2 *Importance of compactibility* 462
 - 19.3.5.3 *Determination of compaction characteristics* 462
 - 19.3.5.4 *Factors affecting compactibility* 463
- 19.3.6 *Content uniformity* 463
 - 19.3.6.1 *Importance of uniform mixing* 463
 - 19.3.6.2 *Factors affecting mixing uniformity* 463
 - 19.3.6.3 *Assessment of content uniformity* 464
 - 19.3.6.4 *Addressing content nonuniformity issues* 465
- 19.4 *Powder processing* 465
 - 19.4.1 *Increasing particle size: Granulation* 465
 - 19.4.1.1 *Dry granulation* 466
 - 19.4.1.2 *Wet granulation* 467
 - 19.4.2 *Decreasing particle size: Comminution or milling* 470
 - 19.4.2.1 *Techniques for particle size reduction* 471
 - 19.4.2.2 *Selection of size reduction technique* 471
- 19.5 *Powders as dosage forms* 472
 - 19.5.1 *Types of powder dosage forms* 472
 - 19.5.1.1 *Oral powders in unit dose sachets* 472
 - 19.5.1.2 *Powders for oral solution or suspension* 473
 - 19.5.1.3 *Bulk powders for oral administration* 473
 - 19.5.1.4 *Effervescent granules* 473

- 19.5.1.5 *Dusting powders* 473
- 19.5.1.6 *Dry powder inhalers* 474
- 19.5.2 *Advantages of extemporaneous compounding of powders* 474
- 19.5.3 *Extemporaneous compounding techniques* 474
- Review questions* 475
- References* 477
- Further reading* 477

20 Tablets 479

- 20.1 *Introduction* 479
- 20.2 *Types of tablets* 480
 - 20.2.1 *Swallowable tablets* 480
 - 20.2.2 *Effervescent tablets* 480
 - 20.2.3 *Chewable tablets* 480
 - 20.2.4 *Buccal and sublingual tablets* 488
 - 20.2.5 *Lozenges* 488
 - 20.2.6 *Coated tablets* 488
 - 20.2.7 *Enteric-coated tablets* 490
 - 20.2.8 *Immediate release tablets* 491
 - 20.2.9 *Controlled release tablets* 491
- 20.3 *Tablet formulation* 492
 - 20.3.1 *Diluents* 492
 - 20.3.2 *Adsorbents* 495
 - 20.3.3 *Granulating fluid* 495
 - 20.3.4 *Binders* 495
 - 20.3.5 *Glidants* 496
 - 20.3.6 *Lubricants* 496
 - 20.3.7 *Disintegrants* 496
 - 20.3.8 *Miscellaneous* 497
- 20.4 *Manufacturing of tablets* 497
 - 20.4.1 *Requirements for tableting* 497
 - 20.4.2 *Powder flow and compressibility* 498
 - 20.4.3 *Types of manufacturing processes* 499
 - 20.4.4 *Packaging and handling considerations* 502
- 20.5 *Evaluation of tablets* 502
 - 20.5.1 *Appearance* 502
 - 20.5.2 *Uniformity of content* 503
 - 20.5.3 *Hardness* 503
 - 20.5.4 *Friability* 503

- 20.5.5 *Weight uniformity* 503
- 20.5.6 *Disintegration* 503
- 20.5.7 *Dissolution* 504
- 20.6 *Relationship among disintegration, dissolution, and absorption* 504
- Review questions* 506
- Further reading* 507

21 Capsules 509

- 21.1 *Introduction* 509
- 21.2 *Hard gelatin capsules* 511
 - 21.2.1 *Advantages and disadvantages of hard gelatin capsules* 512
 - 21.2.1.1 *Comparison with tablets* 512
 - 21.2.1.2 *Comparison with soft gelatin capsules* 513
 - 21.2.2 *Solid-filled hard gelatin capsules* 513
 - 21.2.2.1 *Main applications* 513
 - 21.2.2.2 *Formulation considerations* 514
 - 21.2.2.3 *Formulation components* 515
 - 21.2.2.4 *Manufacturing process* 516
 - 21.2.3 *Liquid- and semisolid-filled hard gelatin capsules* 518
 - 21.2.3.1 *Main applications* 518
 - 21.2.3.2 *Formulation considerations* 520
 - 21.2.3.3 *Formulation components* 520
 - 21.2.3.4 *Manufacturing process* 520
- 21.3 *Soft gelatin capsules* 521
 - 21.3.1 *Advantages and disadvantages of soft gelatin capsules* 521
 - 21.3.2 *Drivers for development of soft gelatin capsules* 522
 - 21.3.3 *Formulation of soft gelatin capsule shell* 522
 - 21.3.4 *Drug formulation for encapsulation in soft gelatin capsules* 524
 - 21.3.5 *Manufacturing process* 525
 - 21.3.6 *Nongelatin soft capsules* 526
- 21.4 *Evaluation of capsule drug products* 527
 - 21.4.1 *In-process tests* 527
 - 21.4.2 *Finished product quality control tests* 527
 - 21.4.2.1 *Permeability and sealing* 527
 - 21.4.2.2 *Potency and impurity content* 527

- 21.4.2.3 *Average weight and weight variation* 528
- 21.4.2.4 *Uniformity of content* 528
- 21.4.2.5 *Disintegration* 528
- 21.4.2.6 *Dissolution* 528
- 21.4.2.7 *Moisture content* 529
- 21.4.2.8 *Microbial content* 529
- 21.5 *Shelf-life tests* 529
- Review questions* 530
- Further reading* 530

22 Parenteral drug products 533

- 22.1 *Introduction* 533
- 22.2 *Parenteral routes of administration* 534
 - 22.2.1 *Intravenous route* 534
 - 22.2.2 *Intramuscular route* 535
 - 22.2.3 *Subcutaneous route* 535
 - 22.2.4 *Other routes* 535
 - 22.2.5 *Rate and extent of absorption* 536
 - 22.2.6 *Factors affecting selection of route* 536
- 22.3 *Types of parenteral dosage forms* 537
 - 22.3.1 *Small-volume parenterals versus large-volume parenterals* 537
 - 22.3.2 *Injections versus infusions* 537
 - 22.3.3 *Types of formulations* 537
 - 22.3.3.1 *Solutions* 538
 - 22.3.3.2 *Suspensions* 538
 - 22.3.3.3 *Emulsions* 539
- 22.4 *Quality attributes and evaluation* 539
 - 22.4.1 *Sterility* 539
 - 22.4.2 *Pyrogens* 540
 - 22.4.2.1 *Endotoxins, exotoxins, and pyrogens* 540
 - 22.4.2.2 *Endotoxin components and tolerance limits* 540
 - 22.4.2.3 *Sources* 540
 - 22.4.2.4 *Depyrogenation* 540
 - 22.4.2.5 *Detection* 541
 - 22.4.3 *Particulate matters* 541
- 22.5 *Formulation components* 541

- 22.6 *Sterilization* 542
 - 22.6.1 *Filtration* 543
 - 22.6.2 *Dry heat sterilization* 543
 - 22.6.3 *Steam sterilization (autoclaving)* 543
 - 22.6.4 *Radiation sterilization* 543
- Review questions* 544
- Further reading* 544

23 Semisolid dosage forms 547

- 23.1 *Introduction* 547
- 23.2 *Ointments* 548
 - 23.2.1 *Types of ointment bases* 548
 - 23.2.1.1 *Hydrocarbon bases* 548
 - 23.2.1.2 *Absorption bases* 550
 - 23.2.1.3 *Emulsion or water-removable bases and creams* 551
 - 23.2.1.4 *Water-soluble bases* 552
 - 23.2.2 *Selection of ointment bases* 553
 - 23.2.3 *Methods of incorporation of drugs into ointment bases* 554
- 23.3 *Creams* 554
- 23.4 *Gels and jellies* 555
 - 23.4.1 *Gels* 555
 - 23.4.2 *Jellies* 556
- 23.5 *Lotions* 557
- 23.6 *Pastes* 557
- 23.7 *Foams* 558
- 23.8 *Manufacturing processes* 558
 - 23.8.1 *Laboratory scale* 558
 - 23.8.2 *Industrial scale* 559
- 23.9 *Analysis of semisolid dosage forms* 560
- Review questions* 560
- Further reading* 561

24 Inserts, implants, and devices 563

- 24.1 *Introduction* 563
- 24.2 *Inserts* 564
 - 24.2.1 *Ocular inserts* 564
 - 24.2.2 *Suppositories* 565
 - 24.2.2.1 *Types of suppositories* 566

24.2.2.2	<i>Suppository bases</i>	566
24.2.2.3	<i>Manufacturing process and formulation considerations</i>	567
24.2.3	<i>Vaginal rings</i>	568
24.3	<i>Implants</i>	568
24.3.1	<i>Types of implants based on drug release mechanism</i>	568
24.3.1.1	<i>Diffusion-controlled implants</i>	569
24.3.1.2	<i>Osmotic minipumps</i>	569
24.3.2	<i>Types of implants based on clinical use</i>	571
24.3.2.1	<i>Cardiac implants</i>	572
24.3.2.2	<i>Dental implants</i>	572
24.3.2.3	<i>Urological and penal implants</i>	572
24.3.2.4	<i>Breast implants</i>	573
24.3.2.5	<i>Ophthalmic implants</i>	573
24.3.2.6	<i>Dermal or tissue implants</i>	573
24.4	<i>Devices</i>	574
24.4.1	<i>Inhaler devices for pulmonary drug delivery</i>	574
24.4.1.1	<i>Nebulizers</i>	576
24.4.1.2	<i>Metered-dose inhalers</i>	577
24.4.1.3	<i>Dry powder inhalers</i>	577
24.4.2	<i>Intrauterine devices</i>	578
24.4.3	<i>Subcutaneous devices</i>	579
	<i>Review questions</i>	580
	<i>Further reading</i>	581

25 Protein and peptide drug delivery 583

25.1	<i>Introduction</i>	583
25.2	<i>Structure</i>	586
25.2.1	<i>Amino acids</i>	587
25.2.2	<i>Primary structure</i>	591
25.2.3	<i>Secondary structure</i>	591
25.2.4	<i>Tertiary structure</i>	592
25.2.5	<i>Quaternary structure</i>	592
25.3	<i>Types of protein and peptide therapeutics</i>	592
25.3.1	<i>Antibodies</i>	592
25.3.2	<i>Hormones and physiological proteins</i>	595
25.3.3	<i>Chemically modified proteins and peptides</i>	595
25.3.3.1	<i>Conjugation with sugars</i>	596
25.3.3.2	<i>PEGylation</i>	596

- 25.3.3.3 *Other protein conjugation approaches* 598
- 25.3.3.4 *Antibody drug conjugates* 598
- 25.4 *Protein characterization* 598
 - 25.4.1 *Biophysical characterization* 598
 - 25.4.2 *Physicochemical characterization* 599
 - 25.4.2.1 *Solubility* 599
 - 25.4.2.2 *Hydrophobicity* 600
- 25.5 *Instability* 601
 - 25.5.1 *Physical instability* 601
 - 25.5.1.1 *Denaturation* 601
 - 25.5.1.2 *Aggregation and precipitation* 602
 - 25.5.1.3 *Surface adsorption* 603
 - 25.5.2 *Chemical instability* 603
 - 25.5.2.1 *Hydrolysis* 604
 - 25.5.2.2 *Deamidation* 604
 - 25.5.2.3 *Oxidation* 605
 - 25.5.2.4 *Racemization* 606
 - 25.5.2.5 *Disulfide exchange* 606
 - 25.5.2.6 *Maillard reaction* 606
- 25.6 *Antigenicity and immunogenicity* 607
- 25.7 *Drug product formulation and process* 608
 - 25.7.1 *Route of administration* 608
 - 25.7.2 *Type of formulation* 609
 - 25.7.3 *Formulation components* 610
 - 25.7.4 *Manufacturing processes* 611
 - 25.7.4.1 *Protein solution* 611
 - 25.7.4.2 *Lyophilization* 612
- Review questions* 613
- Further reading* 615

26 Biotechnology-based drugs

617

- 26.1 *Introduction* 617
- 26.2 *Gene and gene expression* 618
- 26.3 *Gene silencing* 618
- 26.4 *Gene silencing technologies* 619
 - 26.4.1 *Antisense oligonucleotides* 619
 - 26.4.2 *Triplex-forming oligonucleotides* 620
 - 26.4.3 *Peptide nucleic acids* 621
 - 26.4.4 *Antisense RNA* 621
 - 26.4.5 *MicroRNA* 622

26.4.6	<i>Aptamers</i>	622
26.4.7	<i>Ribozymes</i>	622
26.4.8	<i>RNA interference</i>	622
26.5	<i>Gene therapy</i>	624
26.5.1	<i>Retroviral vector</i>	624
26.5.1.1	<i>MuLV</i>	625
26.5.1.2	<i>Lentiviruses</i>	625
26.5.2	<i>Adenoviral vectors</i>	626
26.5.3	<i>Adeno-associated virus vectors</i>	626
26.5.4	<i>Herpes simplex virus vectors</i>	626
26.5.5	<i>Nonviral gene expression system:</i> <i>Plasmid vectors</i>	627
26.5.6	<i>Gene delivery systems</i>	628
26.5.6.1	<i>Lipid-based gene delivery</i>	629
26.5.6.2	<i>Peptide-based gene delivery</i>	630
26.5.6.3	<i>Polymer-based gene delivery</i>	631
	<i>Review questions</i>	631
	<i>Further reading</i>	632
	<i>Answers to review questions</i>	633
	<i>Index</i>	665



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Foreword

Education and practice of the pharmaceutical sciences are rapidly evolving in the modern times, not only with the new ways of doing things enabled by technological advancements of the twenty-first century—but also by the advent of new medicines and modalities of drug therapy. As much as the basic sciences and the fundamental principles of pharmaceutical sciences remain sound, there is an increasing need to integrate the education of dosage forms and drug delivery with the current research and contemporary practices in the current biopharmaceutical industry. It is here that this book—coauthored by leading scientists in both academia and industry—makes a strong impact by presenting the basic principles in a succinct manner that affords a deeper understanding of their reduction to practice.

The revised and expanded third edition of *Pharmaceutical Dosage Forms and Drug Delivery* provides greater emphasis to the multidisciplinary nature of drug discovery and development. The third edition has a new chapter on “Drug Discovery” and the authors have significantly updated and modified the chapter on “Drug Development and Regulatory Processes.” These revised chapters provide not only an industry perspective of current practices in pharmaceutical sciences, they also share interdisciplinary nature of *what it takes to discover and bring a new drug to the market* by equally emphasizing the role of regulatory authorities and decision-making criteria in a stage-gate process of drug development.

Modern drug discovery is facing increasing challenges of identifying new drug targets and accessing the difficult-to-reach targets. Although early years of drug discovery focused predominantly on extracellular and cell-surface targets, recent efforts have refocused on new mechanisms of disease progression and targets that are intracellular and often also intraorganelle. These new frontiers are exemplified by the treatment of hepatitis C infection and the emergence of immuno-oncology and antibody–drug conjugates. Pharmaceutical scientists are increasingly using targeted drug-delivery strategies to address challenges inherent with evolving targets and increasingly complex nature of the therapeutic moieties. This edition includes a new chapter on “Targeted Drug Delivery” that provides a concise and in-depth overview of different strategies as applied in current practice.

A new chapter has been added on “Radiopharmaceuticals” to familiarize the students with the basic principles; their utilization is currently embedded in the current practice of diagnostic and therapeutic medicine, and the emerging paradigms of their use in new drug development. This revised edition has many more changes to improve and update several other chapters of this book.

The recent years have seen an explosive increase in the information and progress in various subdisciplines of pharmaceutical sciences as well as the basic sciences, which forms the foundation of this applied science. This up-to-date book incorporates both the basics of the underlying sciences and the changes currently underway in a balanced fashion to enable a holistic development of the next generation of students.

I am confident that this book will enable a deeper understanding of fundamental principles and a wider perspective of their practice to our next generation of students.

Happy reading!

Courtney Fletcher
University of Nebraska Medical Center

Preface

This book is designed as a textbook for teaching basic principles of pharmaceutics, dosage form design, and drug delivery to the Doctor of Pharmacy (Pharm. D.) students in the United States and Bachelor of Pharmacy (B. Pharm.) students in other countries. Although there are numerous books on the science of pharmaceutics and dosage form design, including *Martin's Physical Pharmacy* and *Pharmaceutical Sciences* by Sinko, *Physicochemical Principles of Pharmacy* by Florence and Attwood, *Pharmaceutics: The Science of Dosage form Design* by Aulton, *Theory and Practice of Contemporary Pharmaceutics* by Ghosh and Jasti, and *Pharmaceutical Sciences* by Remington, these books cover different areas of the discipline in varying depths and provide limited insight into contemporary practices and practical applications. Each of these textbooks, by themselves, does not provide *an integrated approach* to the students. This leads to the students as well as the teachers to refer many textbooks to develop an overall understanding of the basic physicochemical principles and their applications to the design and development of different pharmaceutical dosage forms. In an attempt to overcome these challenges, this book provides a unified perspective of the overall field to the students as well as instructors.

The students need to know the basic physicochemical principles, application of these principles to the design of dosage forms, and the relevance of these principles to the biopharmaceutical aspects of drugs. Another important aspect of teaching that is urgently needed in our Pharm. D. curricula is to expose students to the *latest developments* in the application of biomaterials as well as protein and nucleic acid-based pharmaceutical dosage forms and therapeutics, and various biotechnology-based developments. Various books that are currently taught to students miss these latest developments in the field of pharmaceutics and drug delivery. Exposure of students to these latest developments is critical to the successful training of future pharmacists, because these therapeutic modalities and options are likely to be clinically significant in the future. All these principles and applications need to be integrated in a single textbook, so that the student develops a better and overall understanding of the principles involved in dosage

form design and drug delivery. This book covers an in-depth discussion on what physiochemical parameters can be used for the design, development, and evaluation of biotechnological dosage forms for delivery of proteins, peptides, oligonucleotides, and genes.

What's new in the third edition of Pharmaceutical Dosage Forms and Drug Delivery? This edition is significantly revised and expanded in the content matter of each chapter—to make sure the most recent progress in the field and pharmaceutical research is captured adequately—and expanded to include additional chapters that provide contemporary practices. These new chapters include “Drug Discovery” and “Drug Development” as expanded separate chapters, “Organ Specific Drug Delivery,” and “Radiopharmaceuticals.”

You have an updated, contemporary, new book that can serve as a textbook for Pharm. D. students and a valuable resource for novice in the pharmaceuticals and drug delivery fields.